Compare FBNC & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBNC | TMDX |
|---|---|---|
| Founded | 1934 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 1995 | 2019 |
| Metric | FBNC | TMDX |
|---|---|---|
| Price | $66.27 | $90.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $62.25 | ★ $148.22 |
| AVG Volume (30 Days) | 194.8K | ★ 951.4K |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | 45.65 | ★ 382.18 |
| EPS | ★ 2.35 | 0.61 |
| Revenue | $67,623,000.00 | ★ $605,494,000.00 |
| Revenue This Year | $37.82 | $24.25 |
| Revenue Next Year | $2.30 | $18.75 |
| P/E Ratio | ★ $28.14 | $144.84 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $45.96 | $60.11 |
| 52 Week High | $66.78 | $156.00 |
| Indicator | FBNC | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 60.09 | 67.21 |
| Support Level | $62.13 | $66.64 |
| Resistance Level | $66.18 | $152.95 |
| Average True Range (ATR) | 1.09 | 4.17 |
| MACD | 0.13 | 0.92 |
| Stochastic Oscillator | 81.09 | 92.12 |
First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing, and investment advisory services.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.